Abcuro is developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells.
Affinia is developing next-generation AAV gene therapies for rare and non-rare diseases.
Amolyt is developing therapeutic peptides for rare endocrine and metabolic diseases.
Claris is a pre-clinical stage company focused on novel therapeutics for front of the eye diseases.
FireCyte is developing novel treatment strategies for progressive neurodegenerative diseases of the eye.
Garuda is pioneering off-the shelf, long-term hematopoietic stem cell (LT-HSC)-based cellular therapies.
Co-founded by clinicians from McLean Hospital, InStride offers technology-enhanced mental health treatment for adolescents.
Lyndra is developing orally administered, ultra-long-acting, sustained-release drugs. The pipeline includes therapies for Alzheimer’s disease, HIV, and a once-monthly option for oral contraception.
Mediar is developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
Nocion is developing novel small molecule charged sodium channel blockers, “nocions,” that selectively affect actively firing nociceptors to treat neuroinflammatory indications.
Paros Bio is developing transformative gene therapies for the treatment of Autosomal Dominant Alzheimer’s Disease.
Photys is developing a new class of bifunctional drugs for phosphorylation of kinases to treat cancer.
Pykus is developing a novel intraocular polymer to replace the vitreous humor following retinal surgery.
QurAlis is developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases.
Rippl is pioneering a new care model to expand access to mental health care for seniors, their families, and caregivers.
Rome is unlocking the hidden genome by targeting the RNA "repeatome" to treat autoimmune disease and cancer.
Scorpion is a next-generation precision oncology company.
SeQure Dx applies best-in-class technology to identify and manage the risks of off-target gene-editing agents.
SwanBio is advancing AAV-based gene therapies for the treatment of neurological diseases, including adrenomyeloneuropathy.
Walden BioSciences is transforming the treatment of kidney disease by restoring or preserving podocyte function.
ZielBio is developing targeted therapies against novel targets for cancer.
Since inception, Mass General Brigham Ventures has realized 16 exits, including seven initial public offerings and nine trade sales. These portfolio companies are spearheading novel approaches to diagnose, prevent and treat a wide range of medical conditions.
Acquired by Roche (ADR: RHHBY)
Monoclonal antibody (mAb) therapy for inflammatory diseases including Rheumatoid Arthritis.
Acquired by The Medicines Company (NASDAQ: MDCO)
Novel precision anesthetics.
Acquired by Novartis (NYSE: NVS)
Next-generation immuno-oncology drugs based on T-cell costimulatory targets.
Acquired by InteleRad Medical Systems
Digital diagnostic image sharing platform.
Acquired by Bial Biotech
Novel personalized medicine platform to treat neurodegenerative diseases, targeting the mutant GBA1 gene.
Acquired by eviCore Healthcare
EHR analytics software – extracting insight from information.
Acquired by Alexion (NASDAQ:ALXN)
Advances the fight against autoimmune disease.
Acquired by Merck (NYSE: MRK)
Anti-LAP antibodies: transforming the tumor microenvironment to treat cancer.
IPO June 2020 (NASDAQ: AKUS); acquired by Lilly (NYSE: LLY) Dec. 2022
Precision genetic medicine company focused on inner ear disorders, including sensorineural hearing loss.
IPO Dec. 2017 (NASDAQ: DNLI)
Defeating neurodegenerative diseases.
IPO Feb. 2016 (NASDAQ: EDIT)
Unlocking the power and potential of CRISPR genome editing technology.
IPO April 2020 (NASDAQ: KROS)
Novel treatments for patients suffering from hematologic and musculoskeletal disorders.
IPO June 2018 (NASDAQ: MGTA)
Revolutionizing stem cell transplant as the new treatment paradigm for immunologic and blood-based diseases.
IPO Nov. 2017 (NASDAQ: SPRO)
Anti-infectives targeting Gram-negative bacteria.
IPO June 2018 (NASDAQ:TBIO), acquired by Sanofi (NASDAQ: SNY) Sep. 2021
Developing messenger RNA (mRNA) therapies.
IPO June 2021 (NASDAQ:VERV)
Pioneering single-course gene editing medicines to treat cardiovascular disease.